drugset / Trial / NCT04949191
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.
Timeline
- Start
- 2021-07-08
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Outcome
Outcome not reported
Stopped (Business): “A business decision due to availability of commercial drug and other options for accessing study drug treatment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemigatinib | Small molecule | — | Oral |
| Subject | Retifanlimab | Monoclonal antibody | — | — |